ישראל - עברית - Ministry of Health

dover medical & scientific equipment ltd, israel - factor viii (human); von willebrand factor - אבקה וממס להכנת תמיסה להזרקה - von willebrand factor 1000 iu/vial; factor viii (human) 1000 iu/vial - coagulation factor viii

ישראל - עברית - Ministry of Health

dover medical & scientific equipment ltd, israel - factor viii (human); von willebrand factor - אבקה וממס להכנת תמיסה להזרקה - von willebrand factor 500 iu/vial; factor viii (human) 500 iu/vial - coagulation factor viii

ישראל - עברית - Ministry of Health

eli lilly israel ltd, israel - ixekizumab - תמיסה להזרקה - ixekizumab 80 mg / 1 ml - ixekizumab

ישראל - עברית - Ministry of Health

teva medical marketing ltd. - sodium chloride - תמיסה לאינפוזיה - sodium chloride 0.9 %w/v - sodium chloride

ישראל - עברית - Ministry of Health

comex ltd - cefalexin as sodium - תרחיף להזרקה - cefalexin as sodium 180 mg/ml - cefalexin

ישראל - עברית - Ministry of Health

novartis israel ltd - tisagenlecleucel - tisagenlecleucel

ישראל - עברית - Ministry of Health

sanofi israel ltd - amiodarone hydrochloride - תמיסה להזרקה - amiodarone hydrochloride 50 mg / 1 ml - amiodarone - amiodarone - corronary insufficiency, arrhythmias resistant to other treatments, wolf parkinson white syndrome.

ישראל - עברית - Ministry of Health

pfizer pharmaceuticals israel ltd - tigecycline - אבקה מיובשת בהקפאה לאינפוזיה - tigecycline 50 mg/dose - tigecycline - tigecycline - tygacil is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions listed below for patients 18 years of age and older:complicated skin and skin structure infections:complicated skin and skin structure infections caused by escherichia coli, enterococcus faecalis (vancomycin-susceptible isolates ), staphylococcus aureus (methicillin-susceptible and -resistant isolates), streptococcus agalactiae, streptococcus anginosus grp. (includes s. anginosus, s. intermedius, and s. constellatus), streptococcus pyogenes, enterobacter cloacae, klebsiella pneumoniae, and bacteroides fragilis .complicated intra-abdominal infections:complicated intra-abdominal infections caused by citrobacter freundii, enterobacter cloacae, escherichia coli, klebsiella oxytoca, klebsiella pneumoniae, enterococcus faecalis (vancomycin-susceptible isolates), staphylococcus aureus (methicillin-susceptible and -resistant isolates), streptococcus anginosus grp. (includes s. anginosu

ישראל - עברית - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - tigecycline - אבקה להכנת תמיסה לאינפוזיה - tigecycline 50 mg/dose - tigecycline - tigecycline - tygacil is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions listed below for patients 18 years of age and older:complicated skin and skin structure infections:complicated skin and skin structure infections caused by escherichia coli, enterococcus faecalis (vancomycin-susceptible isolates ), staphylococcus aureus (methicillin-susceptible and -resistant isolates), streptococcus agalactiae, streptococcus anginosus grp. (includes s. anginosus, s. intermedius, and s. constellatus), streptococcus pyogenes, enterobacter cloacae, klebsiella pneumoniae, and bacteroides fragilis .complicated intra-abdominal infections:complicated intra-abdominal infections caused by citrobacter freundii, enterobacter cloacae, escherichia coli, klebsiella oxytoca, klebsiella pneumoniae, enterococcus faecalis (vancomycin-susceptible isolates), staphylococcus aureus (methicillin-susceptible and -resistant isolates), streptococcus anginosus grp. (includes s. anginosu

ישראל - עברית - Ministry of Health

dexcel ltd, israel - clarithromycin - קפליות - clarithromycin 250 mg - clarithromycin - clarithromycin - klaridex is indicated in the treatment of infections caused by one or more susceptible organisms. indications include: lower respiratory tract infections, for example, acute and chronic bronchitis and pneumonia. upper respiratory tract infections, for example, sinusitis and pharyngitis. klaridex is appropriate for initial therapy in community acquired respiratory infections and has been shown to be active in vitro against common and atypical respiratory pathogens as listed in the microbiology section. klaridex is also indicated in skin and soft tissue infections of mild to moderate severity. klaridex is also indicated in combination with proton pump inhibitor for the eradication of h. pylori in patients with proven duodenal ulcer. treatment of mycobacterium avium complex infection in aids patients.